Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
4.79 ^CNY	+6.92%		+1.70%	-48.72%

Jul. 02	Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on June 28, 2024.	CI
Jun. 27	Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	CI

Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on December 1, 2020.

January 04, 2021 at 02:32 pm EST

From December 1, 2020 to December 31, 2020, the company has repurchased 1,334,200 shares, representing 0.57% for CNY 50 million. With this, the company has completed the repurchase of 1,334,200 shares, representing 0.57% for CNY 50 million under the buyback announced on December 1, 2020.

Latest news about Guangdong Hybribio Biotech Co.,Ltd.

Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on June 28, 2024.	Jul. 02	CI
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	Jun. 27	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	Jun. 26	CI
Hybribio Biotech Gets Patent for Spinal Muscular Atrophy Gene Kit	May. 20	MT
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China	May. 16	MT
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for the Year 2023	May. 15	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	May. 07	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on February 6, 2024, has closed with 4,445,000 shares, representing 1.51% for CNY 30.1 million.	May. 06	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	Apr. 23	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Guangdong Hybribio Biotech, Subsidiary Get Patent from Brazil for Isolation Method	Mar. 22	MT
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System	Feb. 23	MT
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	Feb. 05	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	Feb. 04	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Two Guangdong Hybribio Biotech Units Get Licenses from Drug Regulator	23-09-04	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Guangdong Hybribio Biotech Registers Gene Testing Kit	23-08-18	MT
Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023	23-07-31	CI
Hybribio Biotech Appoints Chief Medical Officer	23-06-27	MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022.	23-05-24	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on October 26, 2022 has closed with 5,937,000 shares, representing 0.91% for CNY 100 million.	23-05-22	CI
Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023	23-05-12	CI

Chart Guangdong Hybribio Biotech Co.,Ltd.

Duration

Period

Chart Guangdong Hybribio Biotech Co.,Ltd.

More charts

Company Profile

Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.79

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GUANGDONG HYBRIBIO BIOTECH CO.,LTD.	-48.72%	395M
LANTHEUS HOLDINGS, INC.	+99.39%	7.36B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-21.23%	6.62B
DIASORIN S.P.A.	+7.89%	5.73B
AUTOBIO DIAGNOSTICS CO., LTD.	-22.19%	3.46B
ANDON HEALTH CO., LTD.	+6.24%	2.5B
MYRIAD GENETICS, INC.	+35.32%	2.28B
VITROLIFE AB	-7.91%	2.22B
10X GENOMICS, INC.	-69.64%	1.88B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-18.50%	1.57B

Diagnostic & Testing Substances